Serum MiR-204 is an Early Biomarker of Type 1 Diabetes-associated Pancreatic Beta-cell Loss

Overview

Journal Am J Physiol Endocrinol Metab

Publisher American Physiological Society

Specialties Endocrinology
Physiology

Date 2019 Aug 14

PMID 31408375

Citations 25

Authors

Guanlan Xu

Lance A Thielen

Junqin Chen

Truman B Grayson

Tiffany Grimes

S Louis Bridges Jr

Hubert M Tse

Blair Smith

Rakesh Patel

Peng Li

Carmella Evans-Molina

Fernando Ovalle

Anath Shalev

Affiliations

Soon will be listed here.

Abstract

Pancreatic beta-cell death is a major factor in the pathogenesis of type 1 diabetes (T1D), but straightforward methods to measure beta-cell loss in humans are lacking, underlining the need for novel biomarkers. Using studies in INS-1 cells, human islets, diabetic mice, and serum samples of subjects with T1D at different stages, we have identified serum miR-204 as an early biomarker of T1D-associated beta-cell loss in humans. MiR-204 is a highly enriched microRNA in human beta-cells, and we found that it is released from dying beta-cells and detectable in human serum. We further discovered that serum miR-204 was elevated in children and adults with T1D and in autoantibody-positive at-risk subjects but not in type 2 diabetes or other autoimmune diseases and was inversely correlated with remaining beta-cell function in recent-onset T1D. Thus, serum miR-204 may provide a much needed novel approach to assess early T1D-associated human beta-cell loss even before onset of overt disease.

Citing Articles

Small RNA-Seq and real time rt-qPCR reveal islet miRNA released under stress conditions.

Aljani B, Lindner A, Weigelt M, Zhao M, Sharma V, Bonifacio E Islets. 2024; 16(1):2392343.

PMID: 39154325 PMC: 11332650. DOI: 10.1080/19382014.2024.2392343.

Approaches to Measuring Beta Cell Reserve and Defining Partial Clinical Remission in Paediatric Type 1 Diabetes.

Kennedy E, Hawkes C Children (Basel). 2024; 11(2).

PMID: 38397298 PMC: 10887271. DOI: 10.3390/children11020186.

"Hyperglycemic Memory": Observational Evidence to Experimental Inference.

Ahmadi M, Ghafouri-Fard S, Najari-Hanjani P, Morshedzadeh F, Malakoutian T, Abbasi M Curr Diabetes Rev. 2024; 21(4):64-78.

PMID: 38369731 DOI: 10.2174/0115733998279869231227091944.

MicroRNAs as novel biomarkers for the diagnosis and treatment of pediatric diseases.

Jeong H, Hwang I Clin Exp Pediatr. 2023; 67(3):119-125.

PMID: 37232075 PMC: 10915459. DOI: 10.3345/cep.2023.00171.

Immunoregulatory Biomarkers of the Remission Phase in Type 1 Diabetes: miR-30d-5p Modulates PD-1 Expression and Regulatory T Cell Expansion.

Gomez-Munoz L, Perna-Barrull D, Murillo M, Armengol M, Alcalde M, Catala M Noncoding RNA. 2023; 9(2).

PMID: 36960962 PMC: 10037622. DOI: 10.3390/ncrna9020017.

References

Filios S, Shalev A . β-Cell MicroRNAs: Small but Powerful. Diabetes. 2015; 64(11):3631-44. PMC: 4613982. DOI: 10.2337/db15-0831. View

Assmann T, Recamonde-Mendoza M, Punales M, Tschiedel B, Canani L, Crispim D . MicroRNA expression profile in plasma from type 1 diabetic patients: Case-control study and bioinformatic analysis. Diabetes Res Clin Pract. 2018; 141:35-46. DOI: 10.1016/j.diabres.2018.03.044. View

Erener S, Marwaha A, Tan R, Panagiotopoulos C, Kieffer T . Profiling of circulating microRNAs in children with recent onset of type 1 diabetes. JCI Insight. 2017; 2(4):e89656. PMC: 5313074. DOI: 10.1172/jci.insight.89656. View

Liu L, Yan J, Xu H, Zhu Y, Liang H, Pan W . Two Novel MicroRNA Biomarkers Related to β-Cell Damage and Their Potential Values for Early Diagnosis of Type 1 Diabetes. J Clin Endocrinol Metab. 2018; 103(4):1320-1329. DOI: 10.1210/jc.2017-01417. View

Greenbaum C, Beam C, Boulware D, Gitelman S, Gottlieb P, Herold K . Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data. Diabetes. 2012; 61(8):2066-73. PMC: 3402330. DOI: 10.2337/db11-1538. View

Fisher M, Watkins R, Blum J, Evans-Molina C, Chalasani N, DiMeglio L . Elevations in Circulating Methylated and Unmethylated Preproinsulin DNA in New-Onset Type 1 Diabetes. Diabetes. 2015; 64(11):3867-72. PMC: 4613977. DOI: 10.2337/db15-0430. View

Chen C, Cohrs C, Stertmann J, Bozsak R, Speier S . Human beta cell mass and function in diabetes: Recent advances in knowledge and technologies to understand disease pathogenesis. Mol Metab. 2017; 6(9):943-957. PMC: 5605733. DOI: 10.1016/j.molmet.2017.06.019. View

Grunnet L, Aikin R, Tonnesen M, Paraskevas S, Blaabjerg L, Storling J . Proinflammatory cytokines activate the intrinsic apoptotic pathway in beta-cells. Diabetes. 2009; 58(8):1807-15. PMC: 2712790. DOI: 10.2337/db08-0178. View

Palmer J, Fleming G, Greenbaum C, Herold K, Jansa L, Kolb H . C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001. Diabetes. 2003; 53(1):250-64. DOI: 10.2337/diabetes.53.1.250. View

10.

Xu G, Chen J, Jing G, Grayson T, Shalev A . miR-204 Targets PERK and Regulates UPR Signaling and β-Cell Apoptosis. Mol Endocrinol. 2016; 30(8):917-24. PMC: 4965845. DOI: 10.1210/me.2016-1056. View

11.

Poy M, Eliasson L, Krutzfeldt J, Kuwajima S, Ma X, MacDonald P . A pancreatic islet-specific microRNA regulates insulin secretion. Nature. 2004; 432(7014):226-30. DOI: 10.1038/nature03076. View

12.

van de Bunt M, Gaulton K, Parts L, Moran I, Johnson P, Lindgren C . The miRNA profile of human pancreatic islets and beta-cells and relationship to type 2 diabetes pathogenesis. PLoS One. 2013; 8(1):e55272. PMC: 3555946. DOI: 10.1371/journal.pone.0055272. View

13.

Nielsen L, Wang C, Sorensen K, Bang-Berthelsen C, Hansen L, Andersen M . Circulating levels of microRNA from children with newly diagnosed type 1 diabetes and healthy controls: evidence that miR-25 associates to residual beta-cell function and glycaemic control during disease progression. Exp Diabetes Res. 2012; 2012:896362. PMC: 3398606. DOI: 10.1155/2012/896362. View

14.

Jo S, Chen J, Xu G, Grayson T, Thielen L, Shalev A . miR-204 Controls Glucagon-Like Peptide 1 Receptor Expression and Agonist Function. Diabetes. 2017; 67(2):256-264. PMC: 5780066. DOI: 10.2337/db17-0506. View

15.

Herold K, Usmani-Brown S, Ghazi T, Lebastchi J, Beam C, Bellin M . β cell death and dysfunction during type 1 diabetes development in at-risk individuals. J Clin Invest. 2015; 125(3):1163-73. PMC: 4362259. DOI: 10.1172/JCI78142. View

16.

Guay C, Regazzi R . Circulating microRNAs as novel biomarkers for diabetes mellitus. Nat Rev Endocrinol. 2013; 9(9):513-21. DOI: 10.1038/nrendo.2013.86. View

17.

Greenbaum C, Mandrup-Poulsen T, McGee P, Battelino T, Haastert B, Ludvigsson J . Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes. Diabetes Care. 2008; 31(10):1966-71. PMC: 2551636. DOI: 10.2337/dc07-2451. View

18.

Samandari N, Mirza A, Nielsen L, Kaur S, Hougaard P, Fredheim S . Circulating microRNA levels predict residual beta cell function and glycaemic control in children with type 1 diabetes mellitus. Diabetologia. 2016; 60(2):354-363. DOI: 10.1007/s00125-016-4156-4. View

19.

Mirmira R, Sims E, Syed F, Evans-Molina C . Biomarkers of β-Cell Stress and Death in Type 1 Diabetes. Curr Diab Rep. 2016; 16(10):95. PMC: 5081288. DOI: 10.1007/s11892-016-0783-x. View

20.

Xu G, Chen J, Jing G, Shalev A . Thioredoxin-interacting protein regulates insulin transcription through microRNA-204. Nat Med. 2013; 19(9):1141-6. PMC: 3835787. DOI: 10.1038/nm.3287. View